Jordon-based Hikma Pharmaceuticals (LSE: HIK)has officially announced its plans for the building of a manufacturing plant in Almaty, the largest city of Kazakhstan during the next several years, reports The Pharma Letter’s local correspondent.
Building of the plant is scheduled to begin later this year, and the new facility will fully comply with international Good Manufacturing Practices (GMP) standards, according to Hikma.
$35 million investment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze